Login to Your Account



Trip to the 'would shed': If phase II data hold, Genocea may beat daily genital herpes drugs

By Randy Osborne
Staff Writer

Thursday, March 31, 2016

Genocea Biosciences Inc.'s latest, 12-month, dose-optimization phase II results with its GEN-003 vaccine immunotherapy for genital herpes compare well with those achieved by way of currently available, daily, oral medicine.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription